Viewing Study NCT02706405

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2026-02-21 @ 8:26 AM
Study NCT ID: NCT02706405
Status: TERMINATED
Last Update Posted: 2022-08-24
First Post: 2016-02-24
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Sponsor: Fred Hutchinson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B-Cell Lymphoma, Not Otherwise Specified View
None Recurrent Diffuse Large B-Cell Lymphoma View
None Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma View
None Refractory Diffuse Large B-Cell Lymphoma View
None Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 … View
None Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PD-L1 View
None immunotherapy View
None non-Hodgkin lymphoma View